Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

Authors:

Abstract
Therapy-related secondary myeloid neoplasms constitute a spectrum of diseases, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), which are serious consequences resulting from the transformation of a myeloid clone induced by cytotoxic therapy or ionizing radiation exposure.1-3 From 10% to 20% of patients diagnosed with myeloid neoplasms have a history of exposure to cytotoxic therapy and/or radiotherapy for treatment of an unrelated, primary malignant or benign disease, such as an autoimmune disease (AID).3,4 The basis of radiotherapy- or chemotherapy-related hematologic malignant disease is proposed to be a loss of DNA repair mechanisms and resulting genomic instability.2,5 The most common therapeutic agents implicated are alkylating compounds, antimetabolites, and topoisomerase inhibitors.1-3,6 Medical literature has highlighted therapy-related myeloid neoplasms after treatment of several nonmalignant diseases, especially inflammatory bowel disease1,7-9 and rheumatoid arthritis.8,10,11 Further confounding this risk for myeloid neoplasms is the nature of AID itself, which is characterized by an incessant, chronically activated inflammatory cascade that has been associated with an increased risk for myeloid malignant neoplasms alone.12

This publication has 29 references indexed in Scilit: